HSBC Holdings’s Haemonetics HAE Stock Holding History

HSBC Holdings’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$7.81K	–	3133
2024 Q4	$7.81K	Buy	+100	New	+$8.03K	﹤0.01%	3074
2024 Q2	–	Sell	-27,600	Closed	-$2.36M	–	3035
2024 Q1	$2.36M	Buy	27,600 +10,300	+60%	+$808K	﹤0.01%	1395
2023 Q4	$1.49M	Buy	17,300 +13,200	+322%	+$1.14M	﹤0.01%	1609
2023 Q3	$373K	Buy	+4,100	New	+$366K	﹤0.01%	2099
2023 Q2	–	Sell	-23,800	Closed	-$1.96M	–	2639
2023 Q1	$1.96M	Sell	23,800 -34,300	-59%	-$2.78M	﹤0.01%	1521
2022 Q4	$4.52M	Buy	58,100 +56,300	+3,128%	+$4.53M	0.01%	1296
2022 Q3	$135K	Buy	+1,800	New	+$129K	﹤0.01%	2713
2021 Q4	–	Sell	-39,500	Closed	-$2.79M	–	3294
2021 Q3	$2.79M	Hold	39,500	–	–	﹤0.01%	1394
2021 Q2	$2.63M	Buy	+39,500	New	+$2.8M	﹤0.01%	1333

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HSBC Holdings's HAE Position: Q1 2026 in Review

HSBC Holdings increased its Haemonetics (HAE) stake by 240% in Q1 2026, buying an estimated $1.71M and bringing the position to 37,256 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

HSBC Holdings first reported a position in HAE in Q4 2016 and has held it in 31 quarters since. The position peaked at $22.8M in Q2 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

HSBC Holdings held 37,256 shares of Haemonetics worth $2.1M as of Q1 2026.
HSBC Holdings bought 26,284 Haemonetics shares in Q1 2026, an estimated $1.71M.
Haemonetics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1503 holding.
HSBC Holdings first reported a position in Haemonetics in Q4 2016 and has held it in 31 quarters since.
HSBC Holdings's Haemonetics position peaked at $22.8M in Q2 2018.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.